نتائج البحث - "Caroline Robert"

المصدر: Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38, 33, pp. 3925-3936

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
https://hdl.handle.net/2066/228545Test

6

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial

المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Association

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test

7

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

المؤلفون: Piotr Rutkowski, Sama Ahsan, Jean-Jacques Grob, Matteo S. Carlino, James R. Anderson, Merrick I. Ross, John M. Kirkwood, Jeffrey E. Gershenwald, Caroline Robert, Jason J. Luke, Nageatte Ibrahim, Charles H. Yoon, Peter Mohr, Georgina V. Long, Alexander M.M. Eggermont, Axel Hauschild, Paolo A. Ascierto, Andrew Poklepovic, Richard A. Scolyer

المصدر: Future Oncology. 16:4429-4438

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, medicine.medical_treatment, Dermatologic Surgical Procedures, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Placebo, Disease-Free Survival, Placebos, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Adjuvant therapy, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, Young adult, Child, Melanoma, Neoplasm Staging, Randomized Controlled Trials as Topic, Cross-Over Studies, business.industry, General Medicine, medicine.disease, Crossover study, Clinical trial, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Adjuvant

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a00dd1a28f82ed3c8216b416ba2d53Test
https://doi.org/10.2217/fon-2019-0666Test

8

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

المؤلفون: Peter Hersey, Jean-Jacques Grob, Blanca Homet Moreno, Omid Hamid, Erin Jensen, Tara C. Mitchell, Georgina V. Long, Jedd D. Wolchok, Ana Arance, Anthony M. Joshua, Matteo S. Carlino, Caroline Robert, Laurent Mortier, Jacob Schachter, Jeffrey S. Weber, F. Stephen Hodi, Adil Daud, Scott J. Diede, Antoni Ribas

المصدر: European journal of cancer (Oxford, England : 1990). 157

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d36204dbb77dc73c57b42b2ef7e542Test
https://pubmed.ncbi.nlm.nih.gov/34571336Test

9

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

المساهمون: Intégrité du génome, ARN et cancer, Institut Curie [Paris]-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), University of Zurich, Robert, Caroline

المصدر: European journal of cancer (Oxford, England : 1990)
European Journal of Cancer
European Journal of Cancer, Elsevier, 2021, 144, pp.182-191. ⟨10.1016/j.ejca.2020.11.010⟩

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, [SDV]Life Sciences [q-bio], Immune-checkpoint inhibitors, Pembrolizumab, Gastroenterology, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immune-related adverse events, Monoclonal, 80 and over, 1306 Cancer Research, Melanoma, Humanized, Cancer, Aged, 80 and over, Clinical Trials as Topic, 10177 Dermatology Clinic, Middle Aged, Prognosis, Advanced melanoma, 3. Good health, Immunological, Oncology, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Toxicity, Public Health and Health Services, 2730 Oncology, Female, PD-1 inhibitors, Adult, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Oncology and Carcinogenesis, 610 Medicine & health, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Article, Antibodies, Vaccine Related, 03 medical and health sciences, Young Adult, Meta-Analysis as Topic, Internal medicine, medicine, Humans, In patient, Oncology & Carcinogenesis, Adverse effect, Pneumonitis, Aged, Immunomodulating drugs, business.industry, Evaluation of treatments and therapeutic interventions, medicine.disease, Clinical trial, 030104 developmental biology, Corticosteroid use, Immunization, business, Follow-Up Studies

وصف الملف: application/pdf; 868_Robert_C._et_al._Long-term_safety_of_pembrolizumab_monotherapy_and_relationship_with_clinical_outcome_EJC_2020.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c081e1b4e51d5ab8b097204bced3e77dTest
https://escholarship.org/uc/item/275859csTest

10

Post-shingles granulomatous dermatosis related to anti-programmed cell death 1

المؤلفون: Vincent Ribrag, Jean-Marie Michot, Tony Ibrahim, Peggy Dartigues, David Ghez, Julien Lazarovici, Tarek Assi, Caroline Robert, Christine Mateus, Marie Terroir-Cassou-Mounat, Julien Rossignol, Alina Danu

المصدر: Immunotherapy. 11:591-598

مصطلحات موضوعية: 0301 basic medicine, Herpesvirus 3, Human, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Immune checkpoint inhibitors, Immunology, Pembrolizumab, Antibodies, Monoclonal, Humanized, Herpes Zoster, Skin Diseases, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Programmed cell death 1, Dermatomal, Humans, Immunology and Allergy, Medicine, Adverse effect, Neoplasm Staging, Skin, Granuloma, biology, business.industry, Remission Induction, Cancer, Middle Aged, medicine.disease, Hodgkin Disease, Magnetic Resonance Imaging, Dermatology, Stage IV Hodgkin Lymphoma, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Female, Immunotherapy, Tomography, X-Ray Computed, business, Shingles

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57337d95d1038366e184dcaf5976de42Test
https://doi.org/10.2217/imt-2018-0169Test

تنقيح النتائج